Indoco cuts debt target, USFDA audit still open
Q1 EBITDA margin improved to 10.3% from 3.8%, but management lowered near-term debt repayment goal by ₹30 crore and gave no timeline for USFDA clearance.
— 2 earlier stories on Indoco Remedies Ltd. →What's new
- Management lowered near-term debt repayment target to ₹110 cr from ₹140 cr.
- USFDA audit of Goa sterile plant remains unresolved with no timeline.
- Standalone revenue grew 6% YoY to ₹408 cr; EBITDA margin improved to 10.3%.
Why this matters
The margin recovery shows operational improvement, but the debt pile of ~₹960 cr and ₹100 cr annual interest costs mean cash flow is still under pressure. The unresolved USFDA issue delays new US product approvals, capping growth.
What we're watching
- Timeline for USFDA resolution and new product approvals.
- Debt reduction progress against revised ₹260 cr target over 17-18 months.
- Sustainability of margin improvement beyond the exceptional gain from ophthalmic sale.
The full read
Indoco's Q1 showed operational improvement: EBITDA margins improved to 10.3% on 6% revenue growth. But the balance sheet and regulatory overhangs remain. Management cut its current-year debt repayment target by ₹30 crore to ₹110 crore and now guides for ₹260 crore total repayments over the next 17-18 months. That is a slowdown from the earlier pace. Meanwhile, the USFDA audit of the Goa sterile plant is still open with no end in sight, stalling US launches. The ₹97 crore exceptional gain from the ophthalmology division sale added some cash, but with consolidated debt of ~₹960 crore and annual interest near ₹100 crore, the relief is temporary. The open question is whether the margin recovery is sustainable without the one-off gain and with US headwinds.
Questions answered
- How much did Indoco cut its debt repayment target?
- The company lowered the current-year target from ₹140 crore to ₹110 crore, a reduction of ₹30 crore.
- What is the status of the USFDA audit?
- The audit of the Goa sterile plant remains unresolved with no timeline for resolution, delaying new US product approvals.
- How did Q1 revenue and margins perform?
- Standalone revenue grew 6% YoY to ₹408 crore, while EBITDA margin improved to 10.3% from 3.8% a year earlier.
- What was the exceptional gain in Q1?
- The ophthalmology division divestment contributed a ₹97 crore exceptional gain, providing cash for debt reduction.
- What is Indoco's total debt and interest burden?
- Consolidated debt stood around ₹960 crore as of March, with annual interest costs of nearly ₹100 crore.
- What is the new debt repayment plan?
- Management guided for total repayments of ₹260 crore over the next 17-18 months, including the revised current-year target.
Story so far
All notes on INDOCO →- 28 Jul 2026 · 4:44 PM IST Indoco cuts debt target, USFDA audit still open
- today Indoco's ₹97 cr sale masks core loss; auditor flags subsidiary's future
- today Indoco Q1 profit hinges on ₹97 cr ophthalmic sale gain